Nascent Biotech (NBIO) News Today $0.03 -0.01 (-21.00%) As of 01/14/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period NBiOSHOWCASE 2024 Announces First Biotech Unicorn In Malaysia, Attracts Nearly RM3 Billion Foreign InvestmentJuly 29, 2024 | markets.businessinsider.comNascent Biotech prepares for pivotal Phase II research with fresh manufacturing runApril 16, 2024 | msn.comNascent Biotech Inc.: Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing RunApril 16, 2024 | finanznachrichten.deNascent Biotech Inc.: Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery SystemMarch 19, 2024 | finanznachrichten.deNascent Biotech Inc NBIOMarch 2, 2024 | morningstar.comNascent Biotech Inc.: Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesFebruary 6, 2024 | finanznachrichten.deNascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesFebruary 6, 2024 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under ValuedJanuary 10, 2024 | finanznachrichten.deNascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under ValuedJanuary 9, 2024 | finance.yahoo.comNascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution RiskDecember 19, 2023 | finance.yahoo.comNascent Biotech Granted Japanese Patent for Crossing Blood-Brain BarrierNovember 29, 2023 | finance.yahoo.comIsana Nascent AcademyNovember 15, 2023 | usnews.comChicago to showcase its biotech sector at capital summit next weekOctober 26, 2023 | bizjournals.comA tropical storm could threaten Florida next week. Here’s what we know.September 2, 2023 | washingtonpost.comNascent Biotech to Begin Phase II Clinical Trials for Brain CancerAugust 22, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual MeetingJune 7, 2023 | finanznachrichten.deNascent Biotech Inc.: Nascent Biotech Regains Worldwide Rights for PritumumabMay 26, 2023 | finanznachrichten.deNascent Biotech Regains Worldwide Rights for PritumumabMay 26, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual MeetingMay 9, 2023 | finanznachrichten.deNascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual MeetingMay 9, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and ApprovalApril 18, 2023 | finanznachrichten.deNascent Submits Phase 2 Clinical Research Protocol to FDA for Review and ApprovalApril 18, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Announces the Completion of Its Phase1 Clinical TrialsFebruary 28, 2023 | finanznachrichten.deNascent Announces the Completion of Its Phase1 Clinical TrialsFebruary 28, 2023 | finance.yahoo.comNBIO Nascent Biotech, Inc.February 14, 2023 | seekingalpha.comNascent Biotech Inc.: Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialJanuary 25, 2023 | finanznachrichten.deNascent Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialJanuary 25, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer TrialJanuary 10, 2023 | finanznachrichten.deNascent Enrolls Final Patient Cohort in Phase I Brain Cancer TrialJanuary 10, 2023 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardDecember 20, 2022 | finanznachrichten.deNascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardDecember 20, 2022 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394November 2, 2022 | finanznachrichten.deNascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394November 1, 2022 | finance.yahoo.comNascent Biotech shares fall ~16%, on track for seventh session of losses in eightOctober 6, 2022 | seekingalpha.comNascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchOctober 4, 2022 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerSeptember 15, 2022 | finanznachrichten.deNascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerSeptember 13, 2022 | finance.yahoo.comNascent Biotech - Changing the Biotechnology IndustryAugust 28, 2022 | apnews.comNascent Biotech, Inc. (NBIO)August 27, 2022 | finance.yahoo.comChina Dongsheng International Change of Officers and DirectorsAugust 16, 2022 | nz.finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional PatentJuly 19, 2022 | finanznachrichten.deNascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional PatentJuly 19, 2022 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerJune 7, 2022 | finanznachrichten.deNascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerJune 7, 2022 | finance.yahoo.comNascent Biotech Inc.: Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsMay 6, 2022 | finanznachrichten.deNascent Biotech approaching final cohort for its Phase I clinical study to treat brain cancerMay 4, 2022 | proactiveinvestors.comNascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsMay 4, 2022 | apnews.comNascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsMay 4, 2022 | finance.yahoo.comNascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal AntibodyApril 12, 2022 | finance.yahoo.comThe Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug TrialMarch 8, 2022 | finance.yahoo.com Get Nascent Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIO Media Mentions By Week NBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIO News Sentiment▼0.000.78▲Average Medical News Sentiment NBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIO Articles This Week▼00▲NBIO Articles Average Week Get Nascent Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FFNTF News Today AGNPF News Today ALST News Today HIPH News Today LEAS News Today ARNI News Today AZNCF News Today AVVH News Today AXIM News Today BTMDW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NBIO) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nascent Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nascent Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIO Stock Alerts